Search API

Syphilis Vaccines

Syphilis Vaccines 2024

As of April 2024, the U.S. Food and Drug Administration (FDA), the United Kingdom's NHS, and the European Medicines Agency (EMA) have not approved a syphilis prevention vaccine. The U.S. National Institute of Allergy and Infectious Diseases (NIAID) funds Sexually Transmitted Infection (STI) cooperative vaccine research centers (CRCs) to advance the development of syphilis vaccine concepts. In their pursuit of a syphilis vaccine, the CRCs are investigating the structure of proteins on the outer membrane (layer) of T. pallidum bacteria as potential vaccine targets and developing the tri-antigen vaccine featured at the STI & HIV World Congress. The continued prevalence and severity of Syphilis and Congenital Syphilis (CS) in women and infants highlights the need for an effective preventive vaccine, says the World Health Organization (WHO).

Syphilis Vaccine Candidates

April 6, 2023 - Frontiers in Immunology published Syphilis vaccine: challenges, controversies, and opportunities. "In this review, researchers describe what is known about the Treponema pallidum subspecie pallidum (TPA) immune response and the main mechanisms this pathogen uses to evade it. They also emphasize the importance of integrating this knowledge, in conjunction with the characterization of outer membrane proteins, to expedite the development of a syphilis vaccine that can protect against TPA infection.

March 1, 2023 - The U.S. NIAID seeks applicants who can develop advanced vaccines for STI pathogens with limited product development pipeline candidates.

December 12, 2022 - A study showed that immunization with a TprC/TprK/Tp0751 tri-antigen cocktail protects animals from progressive syphilis lesions and substantially inhibits the dissemination of the infection.

July 28, 2022 - The journal Frontiers in Immunology published: Notes on syphilis vaccine development. Herein, we overview current technologies and approaches employed in syphilis vaccinology and possible directions to develop a vaccine that could be pivotal to future syphilis control and elimination initiatives.

November 25, 2021 - Original Research: Two Potential Syphilis Vaccine Candidates Inhibit Dissemination of Treponema Pallidum. These results provide novel and critical information for understanding the pathogenic mechanisms of spirochetes and the development of spirochete-specific subunit vaccines. Furthermore, these findings indicate that Tp0136 and Tp0663 are promising syphilis vaccine candidates.

Syphilis Cases in the United States

The U.S. Centers for Disease Control and Prevention (CDC) confirmed that the rate of congenital syphilis among American Indians and Alaska Natives was triple the rate for African Americans and nearly 12 times the rate for white babies in 2022. The CDC reported over 3,700 CS cases in 2022, a one-year increase of 30%. In 2021, the state of California led Primary and Secondary Syphilis case reports.

Syphilis Testing

On February 8, 2024, new CDC syphilis testing recommendations were issued supporting a diagnosis of syphilis, including serologic testing and methods for the identification of the causative agent Treponema pallidum.

National Syphilis and Congenital Syphilis Syndemic Federal Task Force

Announced in 2023, the National Syphilis and Congenital Syphilis Syndemic Federal Task Force is utilizing HHS agencies, its expertise, and its stakeholder network to respond to the U.S. syphilis and congenital syphilis epidemic. 

Syphilis Treatments

The U.S. HHS Healthy People 2030 goal focuses on reducing women with syphilis who can also pass the virus to their children during pregnancy. The CDC's Vital Signs report published on November 7, 2023, confirmed about 88% of CS cases could be prevented by timely testing and adequate treatment during pregnancy. The Syphilis in Pregnancy Study (SIPS) is monitoring the outcomes of pregnant people diagnosed with and treated for syphilis, as well as the health outcomes of their infants. 

A new study presented at IDWeek 2023 found a single dose of benzathine penicillin G (BPG) is effective against early syphilis regardless of HIV status. The U.S. CDC recommends a single injection of BPG, indicating it can cure early syphilis and primary, secondary, and latent infections. However, three BPG doses at 1-week intervals for more severe infections, including late latent syphilis and latent syphilis of unknown duration. Bicillin L-A® is the first-line recommended treatment for syphilis and the only recommended treatment option for some patients. Benzathine penicillin G is the WHO and CDC's only recommended treatment for syphilis during a woman's pregnancy.

On January 10, 2024, the FDA's website confirmed the agency would temporarily allow the importation of Laboratoires Delbert's injectable benzathine penicillin G, Extencilline, Powder, and diluent for reconstitution for injection, 1,200,000 units and 2,400,000 units with Foreign, non-U.S. Labeling to Address Supply Shortage.

The University of California, San Francisco, led a phase 4 clinical trial that concluded the combined incidence of syphilis was lower by two-thirds with doxycycline postexposure prophylaxis than with standard care.

Syphilis Outbreaks

Syphilis is a curable bacterial sexually transmitted infection (STI). If untreated, it can cause serious health issues, says the WHO. People can get syphilis by direct contact with a syphilis sore during vaginal, anal, or oral sex, and syphilis can spread from a mother with syphilis to her unborn baby. The U.S.Health Resources and Services Administration (HRSA), in partnership with the Indian Health Service (IHS), noted in July 2023 the rate of syphilis within highly impacted jurisdictions in Alaska, Arizona, Montana, Nebraska, New Mexico, Oregon, and South Dakota.

Japan's National Institute of Infectious Diseases reported 14,906 syphilis cases in 2023, a record high for the third consecutive year. Tokyo accounted for the most cases, with 3,658, followed by Osaka (1,967).

Syphilis News

January 10, 2024—The U.S. FDA is allowing the importation of penicillin to combat an increase in syphilis cases in the U.S.

November 22, 2023 - The JAMA Network published - 90% of Congenital Syphilis Cases Could Have Been Prevented.

November 7, 2023 - The U.S. CDC published - Syphilis in Babies Reflects Health System Failures.

September 15, 2023 - Dr. Helen Fifer, senior author and lead microbiologist for bacterial sexually transmitted infections at the UK Health Security Agency, said in a press release, "We are seeing record levels of STIs (London), including syphilis."

April 2, 2023 - The Washington Post reported reasons syphilis is surging among the U.S.

6 min read
Last Reviewed: 
Wednesday, April 10, 2024 - 08:10
Description: 
Syphilis vaccines continue to be developed, but no vaccine candidate has been US FDA approved.
0 min read

The Kaiser Family Foundation's (KFF) recent analysis of the Household Pulse Survey says there is still a great deal of uncertainty about long COVID and whether there will be increased long COVID cases.

Estimates of the effects of long COVID on the workforce range from about 500,000 to as many as 4 million people, as of January 26, 2023.

The recent KFF online survey administered by the Centers for Disease Control and Prevention found that the percentage of respondents who have had COVID-19 and currently report long COVID symptoms declined from 19% in June 2022 to 11% in January 2023.

And the share of people who have ever reported long COVID fell from 35% to 28% over the same period.

Among people with long COVID, 79% report having limitations to their day-to-day activities, and 27% characterize the limitations as significant. 

Previously, the Department of Health and Human Services released in August 2022, a National Research Action Plan on long COVID aimed at providing a call to action for public and private researchers to accelerate their work.

And the federal RECOVER initiative aims to understand how people recover and why some people don’t. 

Vaccine Treats: 
Image: 
Image Caption: 
KFF Jan 2023 the Percentage who Currently Have Long COVID is Declining
Live Blog Update Author: 
Location Tags: 
Zika Virus Caribbean Islands
Zika virus confirmed in Barbados Puerto Rico Costa Rico
0 min read

The Pan American Health Organization (PAHO) updated its Arboviral situation summary today with data indicating that a coral island in the Lesser Antilles of the West Indies was confronted with an extensive Zika virus (ZIKV) outbreak last year.

Zika transmission can occur in most areas where the mosquito Aedes aegypti is found. This means there is the potential for transmission throughout much of the Caribbean Islands, says the PAHO.

In 2022, the PAHO reported a total of 37,869 ZIKV cases in the Region of the Americas in 15 out of 52 countries and territories. 

The most significant number of Zika cases in the Region was reported by Brazil, with 34,176.

But on a cumulative incidence per 100,000 population basis. Barbados, with about 280,000 residents, led the Region at 48.

Brazil's rate was just 16, based on a population of 214 million.

To alert international visitors of their potential ZIKV health risk when visiting Barbados, the U.S. Centers for Disease Control and Prevention (CDC) issued an Alert - Level 2, Practice Enhanced Precautions. However, the CDC withdrew this Alert on June 30, 2021.

The CDC currently says, 'We do not have accurate information on the current level of risk.'

However, both Canada and the United Kingdom (UK) had enough information to publish ZIKV advice for people visiting Barbados last year.

The UK represented about 50% of all international visitors in 2022.

Because Zika is a cause of severe congenital disabilities, such as microcephaly, the CDC, Canada, and the UK recommend pregnant women and couples trying to become pregnant within the next few months speak with their healthcare providers to carefully consider the risks and possible consequences of travel to areas with risk of Zika.

Furthermore, if a woman is pregnant, she should not visit areas with ZIKV outbreaks, says the CDC.

Furthermore, these countries have not approved a Zika-prevention vaccine as of January 28, 2023.

Vaccine Treats: 
Image: 
Image Caption: 
UK Travel Health Barbados 2023
Live Blog Update Author: 
Location Tags: 
Vaccine: 
Polio eradication in children
Zero polio dose children in seven subnational geographies key to success in 2023
0 min read

The U.S. Department of State recently updated its travel advisory for the Plurinational State of Bolivia in western-central South America.

On January 26, 2023, the State Department's Level 2: Exercise Increased Caution notice highlighted areas of concern.

For the Chapare region, do not travel due to civil unrest. Also called The Chapare, this rural province is in the northern part of the Cochabamba Department in central Bolivia.

Chapare is adjacent to Peru, which also reported civil unrest in 2023. 

The State Department also suggested reconsidering traveling to the Yungas region, which is located further north in Bolivia.

If you visit Bolivia or are in-country, the State Department says to avoid demonstrations and crowds and enroll in STEP to receive embassy alerts and to be located in an emergency.

And, due to ongoing public demonstrations in the southern city of Santa Cruz, the U.S. Consular Agency announced on January 4, 2023, it would remain closed until further notice.

And recommended visitors should limit travel to and around Santa Cruz.

American citizens in Santa Cruz needing urgent consular assistance can contact the Consular Section at the U.S. Embassy La Paz, located at Avenida Arce 2780, La Paz, Bolivia.

At over 3,500m elevation, La Paz is positioned in the Andes' Altiplano plateau near the snow-capped Mt. Illimani, with the world's highest cable car. Or visitors can visit Lake Titicaca, the world's highest navigable lake.

Furthermore, Canada confirmed that roadblocks are common on January 26, 2023, and can lead to significant traffic and public transportation disruptions. The following areas are vulnerable to blockades: along Bolivia–Peru border and roads leading to international airports.

From a health perspective, the U.S. Centers for Disease Control and Prevention (CDC) suggests several pre-visit vaccinations, such as yellow fever.

Yellow fever vaccination is recommended for all travelers ≥9 months of age traveling to areas in elevation and east of the Andes Mountains: the entire departments of Beni, Pando, Santa Cruz, and designated areas of Chuquisaca, Cochabamba, La Paz, and Tarija departments.

In the U.S., the YF-Vax vaccine is available at certified travel clinics and pharmacies.

The article was updated on Jan. 28, 2023.

Vaccine Treats: 
Image: 
Image Caption: 
by Chester Photography
Live Blog Update Author: 
Location Tags: 
0 min read

Roche and its subsidiary TIB Molbiol, recently announced they had developed a COVID-19 PCR test for researchers that detects and differentiates the latest variant of concern, XBB.1.5.

The XBB.1.5 variant is prevalent in the U.S. and is quickly spreading to other countries.

XBB.1.5 is a sub-variant of a SARS-CoV-2 beta coronavirus variant named XBB.

Differentiating emerging variants and understanding their similarities and mutations empowers experts to make predictions about treatment strategies.

The VirSNiP SARS-CoV-2 Spike F486P test is for use on the LightCycler® 480 II and cobas® z 480.

“Roche continues to develop timely diagnostic innovations related to COVID-19 by providing valuable insights - helping scientists and physicians understand this new strain, how it differs from other variants, and the impact it may have on public health,” said Matt Sause, CEO of Roche Diagnostics, in a press release on January 26, 2023.

“Since the start of this global health crisis, Roche has been committed to bringing effective diagnostic solutions to address unmet needs to healthcare communities worldwide.”

The research-use-only test, VirSNiP SARS-CoV-2 Spike F486P, adds to the broad suite of COVID-19 test kits developed by Roche and TIB Molbiol.

In the U.S., the Food and Drug Administration has authorized numerous COVID-19-related tests as of January 27, 2023.

Vaccine Treats: 
Image: 
Image Caption: 
by Ellie from Pixabay
Live Blog Update Author: 
Location Tags: 
COVID-19 vaccinations UK
JCVI interim recommendations on the COVID-19 vaccination for 2023
New York poliovirus wastewater testing
Wastewater testing reaches 215 treatment plants
0 min read

The World Health Organization (WHO) Influenza Update N° 437 report recently confirmed influenza activity decreased globally but remained somewhat elevated due to activity in the northern hemisphere.

In the countries of North America, most indicators of influenza activity decreased to levels similar to or below levels typically observed this time of year.

Influenza A(H3N2) was the predominant virus detected.

In Europe, overall influenza activity decreased.

Many European countries reported high or very high intensity, and more than half reported widespread activity. And various indicators of influenza activity decreased in many countries while others reported increases.

Overall, influenza A viruses predominated with similar proportions of A(H1N1)pdm09 and A(H3N2) influenza viruses detected in primary care sentinel sites but with regional differences.

The full, unedited WHO January 23, 2023 report is posted at this WHO link.

On January 20, 2023, the U.S. CDC FluView week #2 report confirmed seasonal influenza activity was declining in most areas. 

Three regions in the U.S. were below their outpatient respiratory illness baselines for the first time since October 2022.

In the U.S., over 170 million influenza vaccines have been distributed during the 2022-2023 flu season. These flu shots remain generally available at most clinics and pharmacies in the U.S.

Vaccine Treats: 
Image: 
Image Caption: 
WHO Influenza Update N° 437 Jan. 23, 2023
Live Blog Update Author: 
Location Tags: